Helvetia Baloise Holding AG engages in life and non-life insurance, and reinsurance business. It offers life insurance products in the areas of investment-linked, group life, and traditional individual life others; non-life insurance products in the areas of property, motor vehicle, health/accident, liability, engineering, and transport; and pure risk, savings, endowment, and annuity insurance products, as well as pension plans and asset management services. The company also provides marine, aviation, and art insurance. It operates in Switzerland, Spain, Germany, Belgium, Luxembourg, Italian and Austrian Markets, France, and internationally The company was formerly known as Helvetia Holding AG and changed its name to Helvetia Baloise Holding AG in April 2022. Helvetia Baloise Holding AG was incorporated in 2017 and is headquartered in Basel, Switzerland.…
Totalschadenkasko von Helvetia gewinnt Swiss Insurance Innovation Award
Helvetia Baloise Holding (SWX: HBAN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Insurance - Diversified industry, part of the Financial Services sector, and reports about 20,597 employees.
The shares were at 218.20 CHF on 20 November 2026, up 11.7% over 52 weeks. Its 52-week range is 183.40 CHF to 231.00 CHF: the price is 5.5% below the high and 19.0% above the low.
At a market capitalisation of 21.61B CHF, it trades at 41.7 times trailing earnings and 17.3 times forward earnings. The median trailing P/E of its 20 largest Insurance - Diversified peers is 15.0, a premium of 178% for HBAN. It pays a dividend yielding 3.51% (it pays out 147% of its earnings), against a median of 3.98% among the dividend payers in that peer group.
Helvetia Baloise Holding reports return on equity of 4.1%, an operating margin of 7.2% and revenue up 73.0% year over year.
It holds more cash than debt, a net cash position of 26.73B CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 238.00 CHF is 9.1% above the current price. The next earnings report is expected on 17 March 2027.